Attenuation of EGFR-Mediated Cellular Signaling by Sialidase-Mediated Desialylation

Technical Summary: Attenuation of EGFR-Mediated Cellular Signaling by Sialidase-Mediated Desialylation

Problem Statement
Protein glycosylation and phosphorylation are critical, co-occurring post-translational modifications that orchestrate cellular signaling. While receptor tyrosine kinases (RTKs) like the epidermal growth factor receptor (EGFR) are heavily glycosylated, the systems-level crosstalk between extracellular sialylation and intracellular phosphorylation dynamics remains poorly understood. This gap is particularly significant in Clear Cell Renal Cell Carcinoma (ccRCC), a malignancy characterized by metabolic reprogramming and dependency on EGFR signaling. Despite this dependency, EGFR-targeted tyrosine kinase inhibitors (TKIs) like gefitinib have proven clinically ineffective, suggesting that unresolved regulatory layers—potentially involving the glycoproteome—mediate therapeutic resistance. Current genomic data fails to capture these dynamic regulatory layers, necessitating a multi-omics approach to understand how terminal sialic acid occupancy influences kinase activity and therapeutic sensitivity.

Methodology
The study employed an integrated multi-omics pipeline using A498 cells, a model for ccRCC, to systematically map the crosstalk between sialylation and phosphorylation.

• Experimental Design: Cells were subjected to a factorial design involving six conditions: control (C), EGF stimulation (E), EGF + gefitinib (EG), sialidase treatment (S), sialidase + EGF (ES), and sialidase + EGF + gefitinib (ESG). Sialidase was used to enzymatically remove cell-surface sialic acids in situ, followed by stimulation with EGF and/or inhibition with gefitinib.
• Sample Processing: Proteins were extracted, reduced, alkylated, and digested. Peptides were labeled using 18-plex Tandem Mass Tag (TMT) reagents to enable multiplexed quantification.
• Fractionation and Enrichment: The labeled peptides were fractionated. A small aliquot (5%) was reserved for global proteome profiling. The remaining 95% was split for parallel enrichment:
  • Phosphopeptides: Enriched using Immobilized Metal Affinity Chromatography (Fe-IMAC).
  • N-Glycopeptides: Enriched using Mixed-mode Anion Exchange (MAX) chromatography.
• Mass Spectrometry: High-resolution LC-MS/MS analysis was performed on an Orbitrap Fusion Ascend Tribrid mass spectrometer. Data-dependent acquisition (DDA) was used for global and phosphoproteomic runs, while specific parameters (including stepped HCD energy) were optimized for glycoproteomic identification.
• Data Analysis: Data were processed using MS-PyCloud and GPQuest for identification. Quantitative analysis was performed in R using linear models (limma) with empirical Bayes moderation. Differential abundance was assessed across treatment contrasts. Kinase activity was inferred using Kinase-Substrate Enrichment Analysis (KSEA), and pathway enrichment was conducted via DAVID. Protein interaction networks were constructed using STRING and visualized in Cytoscape.

Key Contributions and Results

1. Multi-Omics Landscape and Stability:
   The study established a robust map of the A498 cellular landscape. Quality control confirmed high reproducibility across biological replicates. While the global proteome remained stable over the 2-hour treatment window (indicating changes were due to modifications rather than de novo synthesis), the phosphoproteome and N-glycoproteome exhibited profound sensitivity to perturbations. Sialidase treatment successfully reorganized the N-glycoproteome, with thousands of glycopeptides showing significant abundance changes.

2. Attenuation of EGF-Stimulated Signaling:
   Sialidase-mediated desialylation significantly attenuated EGF-induced signaling. Specifically, the removal of sialic acids suppressed over 200 phosphosites within the MAPK cascade and actin cytoskeleton organization modules. Key regulatory sites, including EGFR Y1197 and S1166, showed significantly reduced phosphorylation in desialylated cells. Kinase-substrate enrichment analysis indicated that desialylation selectively reprogrammed specific kinase-substrate networks (e.g., downregulating AURKB, MAP2K3) rather than causing generalized signaling dampening.

3. Distinct Regulatory Programs: Sialidase vs. Gefitinib:
   Comparative profiling revealed that sialidase treatment exerts a regulatory program distinct from canonical TKI inhibition.

   • Non-Redundancy: While gefitinib targets the intracellular kinase domain, sialidase targets a unique set of phosphosites, particularly those involved in actin cytoskeleton organization, cell-substrate adhesion (e.g., AHNAK, CTTN), and RNA splicing. These sites were often refractory to gefitinib alone.
   • Shared Core: A subset of 112 phosphosites was co-regulated by both treatments, enriched in the MAPK cascade and RTK signaling, including EGFR Y1197 and STAT3 S727.
   • Mechanism: The divergence suggests that surface glycans regulate a distinct suite of structural and cytoskeletal proteins, acting as a "molecular gatekeeper" that prioritizes specific downstream effectors.

4. Synergistic Inhibition (The "Force Multiplier" Effect):
   Combined treatment with sialidase and gefitinib (ESG) resulted in a distinct phosphoproteomic state that was more potent than either agent alone.

   • Additive Suppression: The combination induced a more pronounced downward shift in phosphorylation fold changes, with over 1,500 modulated phosphosites unique to the combined treatment.
   • Mitotic Block: The combined treatment uniquely suppressed phosphosites involved in cell division and mitotic cycle regulation, suggesting a potent block on proliferative signaling that bypasses compensatory pathways typically driving TKI resistance.
   • RPS6 Suppression: Critical nodes like RPS6 (S82) showed significantly greater suppression in the ESG condition, supporting the hypothesis that terminal sialic acids facilitate residual signaling resistant to TKIs alone.

5. Stoichiometric Glyco-Phospho Coupling:
   The study provided site-specific evidence linking extracellular glycan architecture to intracellular signaling.

   • Direct Correlation: The depletion of sialylated N-glycoforms at specific EGFR residues (N413, N444, N603) directly correlated with reduced phosphorylation at key activation sites (Y1197, S1166).
   • Mechanism: The data suggest that the sialic acid cap modulates the conformational equilibrium of the EGFR extracellular domain. The loss of these negatively charged moieties likely increases the energetic barrier for ligand-induced dimerization or alters receptor orientation, acting as a tunable rheostat for growth factor responsiveness.

6. Integrated Network Analysis:
   A global protein interaction network identified four primary functional modules sensitive to desialylation:

   • RTK/Integrin Hubs: A core module involving EGFR, AXL, ERBB2, and ITGB1.
   • Adhesion/Migration: A module centered on CD44, MET, and integrins, suggesting desialylation disrupts crosstalk between growth factor receptors and adhesion pathways.
   • Translation Machinery: A cluster of ribosomal proteins and elongation factors, indicating a retrograde signal from the membrane to the protein synthesis apparatus.
   • Immune Signaling: Modules involving ICAM1, VCAM1, and CD47, suggesting sialylation acts as a checkpoint for receptor accessibility.

Significance and Claims
The paper establishes cell surface sialylation as a critical rheostat for EGFR-mediated signaling, bridging the gap between extracellular glycoprotein architecture and intracellular kinase networks. The authors claim that:

• Glycan Remodeling as a Strategy: Targeting the glycoprotein acts as a "force multiplier," sensitizing RTK-driven malignancies to TKI therapy by collapsing residual signaling hubs (STAT3, STAT5B, mTOR) that are otherwise refractory to kinase inhibition.
• Mechanistic Insight: The study provides systems-level evidence that the sialylation status is a fundamental regulator of the RTK interactome, offering a mechanistic explanation for the failure of TKIs in certain contexts (glyco-resistance).
• Therapeutic Potential: By identifying the glyco-code as a high-precision therapeutic target, the work provides a robust data foundation for developing glycoconjugate-targeted interventions to overcome signaling bypass and therapeutic resistance in ccRCC and other RTK-driven malignancies.

The authors conclude that terminal sialylation is a prerequisite for robust RTK signaling and that enzymatic glycan stripping is a strategic necessity to overcome intrinsic glyco-resistance in tumor cells.